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Studies of Drosophila and mammals have revealed the importance of insulin signaling through phosphati-
dylinositol 3-kinase and the serine/threonine kinase Akt/protein kinase B for the regulation of cell, organ, and
organismal growth. In mammals, three highly conserved proteins, Akt1, Akt2, and Akt3, comprise the Akt
family, of which the first two are required for normal growth and metabolism, respectively. Here we address
the function of Akt3. Like Akt1, Akt3 is not required for the maintenance of normal carbohydrate metabolism
but is essential for the attainment of normal organ size. However, in contrast to Akt1/ mice, which display
a proportional decrease in the sizes of all organs, Akt3/ mice present a selective 20% decrease in brain size.
Moreover, although Akt1- and Akt3-deficient brains are reduced in size to approximately the same degree, the
absence of Akt1 leads to a reduction in cell number, whereas the lack of Akt3 results in smaller and fewer cells.
Finally, mammalian target of rapamycin signaling is attenuated in the brains of Akt3/ but not Akt1/ mice,
suggesting that differential regulation of this pathway contributes to an isoform-specific regulation of cell
growth.
While complex organisms grow toward determinate final
sizes, there must be precise regulation within each tissue as
well as coordination among organs to reach these final sizes
(18, 24). The regulation of both cell number and size contrib-
utes to the establishment of organ size, whereas cell number
appears to be predominant in determining differences between
species. Several factors, including circulating hormones and
metabolites as well as cell-autonomous signaling cascades, con-
trol these processes (31). One of the key extracellular effectors
determining organismal size is insulin-like growth factor 1
(IGF1). As demonstrated by genetic studies with mice, IGF1 is
required for normal embryonic and postnatal growth (4, 43, 44,
59). In addition, IGF1 controls the sizes of individual organs
(43, 59). For example, normal brain growth requires IGF1 (6,
43), as IGF1-deficient brains are reduced in size secondary to
a decrease in both cell number and cell size (6, 15). Similarly,
humans with IGF1 deficiency display severe growth retarda-
tion and suffer from mental retardation (75).
In addition to extracellular factors, the intracellular signal-
ing pathways determining growth are being uncovered. IGF1
acts through the type 1 IGF receptor to modulate an evolu-
tionarily conserved pathway of molecules involved in the reg-
ulation of growth and metabolism (38, 53). For many hor-
mones, including IGF1 and insulin, binding to a receptor
stimulates its protein tyrosine kinase activity, leading to the
phosphorylation of scaffold proteins of the insulin receptor
substrate (IRS) family. IRS proteins assemble complexes that
include a number of potential signaling proteins, of which the
lipid kinase phosphatidylinositol 3-kinase (PI3K) appears to be
the most critical for the maintenance of cell size and prolifer-
ation (10). PI3K catalyzes the generation of phosphatidylino-
sitol 3,4,5-trisphosphate (PIP3), which binds to several signal-
ing molecules, in most cases via a canonical pleckstrin
homology domain. One of these proteins is the phosphoinosit-
ide-dependent kinase 1, which, in cooperation with the poorly
defined phosphoinositide-dependent kinase 2, activates Akt/
protein kinase B (Akt/PKB) by phosphorylation at two critical
residues (8). The lipid phosphatase PTEN negatively regulates
this pathway by converting PIP3 to phosphatidylinositol 4,5-
bisphosphate (PIP2). There is now evidence that the IRS/PI3K/
Akt pathway is involved in the control of organ size in several
model systems (28, 67). Initially, this pathway was established
in the fruit fly Drosophila melanogaster, but it is now clear that
it is also operational in mammals (7, 12, 50, 56, 71). Tissue-
specific activation of this pathway, either by the overexpression
of active PI3K or Akt or by a deletion of PTEN, results in an
increase in the sizes of several organs, including the heart (19,
48, 64–66), the endocrine pancreas (70), the brain (2, 30, 37),
lymphoid tissue (27), the prostate (45, 73), and mammary
glands (23, 39). In all of these cases, the enlargement in organ
size is due at least in part, and often exclusively, to an increase
in cell size. When the activation of Akt occurs early in brain
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development, the brain’s larger size is secondary to increases in
cell size and number, with the latter resulting from the aug-
mented proliferation of neuronal stem cells (30). However, the
activation of this pathway later in development only affects cell
size, and this increase requires the activation of a protein
downstream of IRS/PI3K/Akt, the mammalian target of rapa-
mycin (mTOR) (36, 37). Nutrients as well as growth factors
regulate mTOR, which therefore serves as a critical element in
the coordination of growth with the energy supply. mTOR
activation results in the phosphorylation of downstream targets
such as p70 S6 kinase and 4E-BP1, which regulate protein
translation (55).
In contrast to overexpression studies, only a few reports have
described the effects of reduction in the activity of the IRS/
PI3K/Akt pathway in specific organs (51). In some cases, the
deletion of a gene from all of the tissues of an animal results in
a selective decrease in the size of a single organ. Examples of
this include IRS2 and p70 S6 kinase, two proteins whose elim-
ination leads to a reduction in the brain and the aggregate
mass of the  cells of the pancreas, respectively (57, 63). Re-
garding the former, IRS2-deficient brains are 38% smaller
than normal primarily due to decreased cell proliferation, as
cell size and apoptosis are unaffected (63).
Understanding the requirement of Akt for the determina-
tion of compartment size in mammals is complicated by the
existence of three isoforms encoded by independent genes,
namely, Akt1/PKB, Akt2/PKB, and Akt3/PKB. Despite
their significant homology, Akt1 and Akt2 have distinct func-
tions in the control of growth and metabolism, respectively (13,
16, 17). Akt1-deficient mice display impaired overall growth,
whereas Akt2 null mice are insulin intolerant, demonstrating a
diabetes-like syndrome (13, 16, 17). However, the function of
Akt3 has not yet been assessed by the generation and charac-
terization of Akt3/ mice. The distribution of Akt3 mRNA is
more limited than that of either Akt1 or Akt2 (76). Akt3
mRNA is most highly expressed in the brain and testes, but it
is also detected in fat, lungs, and mammary glands (76). In
human tissue, Northern blot analyses have demonstrated the
highest expression in adult brains, lungs, and kidneys as well as
in fetal hearts, livers, and brains (9). Thus, a critical question to
be addressed is whether Akt3 is important for growth and/or
metabolism and, if so, whether it exerts its effect on particular
cell types.
We report here the generation of mice lacking Akt3, in
which we have observed a selective reduction in brain size.
Moreover, by comparing brains from Akt3/ mice to brains
from Akt1/ mice, we demonstrate isoform-specific mecha-
nisms for the regulation of brain size.
MATERIALS AND METHODS
Generation of Akt3-deficient mice. Using a mouse Akt3 cDNA probe, we
isolated overlapping clones from a 129 mouse genomic library (Stratagene, La
Jolla, Calif.). To introduce a null mutation, we deleted exon 3 (corresponding to
nucleotides 209 to 320 of the mouse cDNA), which introduced a frame shift in
the open reading frame and a truncation of the protein product.
The targeting construct (Fig. 1A) consisted of a 1.9-kb 5 genomic fragment
(NotI-BglII), a loxP-flanked phosphoglycerate kinase-hygromycin-poly(A) cas-
sette in the opposite transcriptional orientation (SalI-BamHI fragment), and a
2.7-kb 3 homology region (SphI-EcoRI). The 5 homology fragment (NotI-
BglII) and the loxP-flanked phosphoglycerate kinase-hygromycin-poly(A) cas-
sette (SalI-BamHI) were cloned into pBKSKII that had been opened with NotI
and SalI. The 3 homology fragment (SphI-EcoRI) was subcloned into pSP73.
The 5 homology selection fragment was released with NotI and SalI and cloned
with the 3 homology fragment (XhoI-EcoRI) into a vector containing the herpes
simplex virus thymidine kinase gene cassette (for negative selection). The tar-
geting construct was linearized with NotI. Genomic DNAs from recombinant
clones were digested with EcoRI and screened by Southern blot analysis. The
probe recognized a 10.4-kb fragment in the wild-type allele and a 5.9-kb fragment
in the targeted allele (Fig. 1B).
Mice were housed in a facility on a 12-h light-dark cycle with free access to
food and water. All procedures were performed in accordance with the policies
of the Institutional Animal Care and Use Committee at the University of Penn-
sylvania.
Mice were genotyped by PCR. Primers 1 (5-GCA TCC ATC CTT GTT CAC
GC) and 2 (5-GGG AGA GAG AAG TGC CAT TGT ATT G) produced an
650-bp band from DNAs of wild-type mice. Primers 1 and 3 (5-GTG GGG
TGG GAT TAG ATA AAT GC) produced an 700-bp band from DNAs
isolated from Akt3/ mice (Fig. 1C).
An antibody to Akt3 was produced by use of a glutathione S-transferase fusion
protein, with amino acids 1 to 147 of AKT3 as the antigen. Antisera were
produced in rabbits and affinity purified by chromatography with the glutathione
S-transferase fusion protein. Western blot analyses with this antibody did not
detect any of the protein in brain extracts from Akt3 knockout animals (Fig. 2A).
Western blot analysis. Brains were homogenized in lysis buffer (50 mM Tris
[pH 8], 250 mM NaCl, 2 mM EDTA, 1% IGEPAL, 200 mM NaF, 1 mM
Na3VO4, complete protease inhibitor cocktail [Roche, Mannheim, Germany]).
Homogenates were clarified by centrifugation, the supernatants were collected,
and the protein concentration was determined by a bicinchoninic acid assay
(BCA) (Pierce, Rockford, Ill.). For examinations of the phosphorylation of the
ribosomal protein S6, 25 g of protein was resolved by sodium dodecyl sulfate–
15% polyacrylamide gel electrophoresis (SDS–15% PAGE). Blots were probed
with anti-phospho-S6 (68) and anti-total S6 (Cell Signaling Technology, Beverly,
Mass.). For the quantification of Akt isoforms, recombinant Akt1, Akt2, and
Akt3 proteins were purchased from Upstate USA, Inc. (Charlottesville, Va.),
and the concentration of each recombinant protein was determined by analysis
FIG. 1. Generation of Akt3-deficient mice. (A) Diagram of the
Akt3 genomic locus and the targeting vector. The positions of the
Southern probe (probe) and PCR primers (1, 2, and 3) are indicated.
(B) Genomic DNAs isolated from wild-type (/), Akt3 heterozygous
(/), and Akt3-null (/) mice were digested with EcoRI and an-
alyzed by Southern blotting. (C) PCR analysis of genomic DNAs from
wild-type (/), Akt3 heterozygous (/), and Akt3-null (/) mice.
Primers 1 and 2 generate a 650-bp band from wild-type DNA, and
primers 1 and 3 generate a 700-bp band from DNA with a targeted
Akt3 allele.
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of a Coomassie blue-stained gel by use of the Odyssey system (LI-COR Bio-
sciences, Lincoln, Nebr.) and a bovine serum albumin standard. A standard curve
for each recombinant Akt protein and dilutions of total brain lysates were
resolved by SDS–10% PAGE, transferred to nitrocellulose, and probed with
isoform-specific antibodies (for Akt1 [Upstate USA, Inc.], Akt2 [68], and Akt3
[described above]). Brain lysates from each isoform-specific knockout animal
were also included on the blot to ensure the specificities of the antibodies.
Secondary antibodies were labeled with IR Dye 800 (Rockland Immunochemi-
cals, Inc., Gilbertsville, Pa.) for quantification by the Odyssey system. The total
amount of Akt protein was determined as the sum of the amounts of the
individual isoforms, and the amount of each isoform was expressed as a percent-
age of the total amount of Akt protein.
Myelin assay. The myelin content in Akt3-deficient brains was measured as
described by Cheng et al. (14). Briefly, brains from control and mutant mice were
homogenized in 0.32 M sucrose. The brain homogenates were layered over an
equal volume of 0.85 M sucrose and centrifuged at 75,000 	 g for 30 min. Myelin
was collected from the interface, osmotically shocked with water on ice for 30
min, and then sedimented by centrifugation at 12,000 	 g for 20 min. The
precipitate was resuspended in 10 mM Tris-HCl (pH 8.0)–1 mM EDTA, and the
protein concentration was determined by a BCA protein assay.
Metabolic analysis. For glucose tolerance tests, glucose (1 g/kg of body weight)
was administered by intraperitoneal injection to fasted conscious mice, and
glucose concentrations were determined by use of a glucometer (Glucometer
Elite XL; Bayer, Tarrytown, N.Y.) from whole blood collected from transversely
sectioned tails. For insulin tolerance tests, porcine insulin (1 U/kg) was admin-
istered by intraperitoneal injection to fasted conscious mice, and glucose con-
centrations were determined by use of a glucometer from whole blood collected
from transversely sectioned tails. Insulin and free fatty acid concentrations were
measured as previously described, and insulin assays were performed by the
Radioimmunoassay Core Facility at the Penn Center for Diabetes (17). A NEFA
C kit (Wako Chemicals USA, Inc., Richmond, Va.) was used to determine free
fatty acid levels.
DNA and protein content. For analyses of DNA and protein content, organs
dissected from age-matched mutant and control animals were weighed and then
homogenized in TNE buffer (10 mM Tris base, 10 mM EDTA, 200 mM NaCl,
pH 7.4). An aliquot of each sample was diluted in TNE buffer containing 0.1 g
of Hoechst 33258/ml for measurement of the DNA content by use of a TD-700
fluorometer (Turner Designs, Sunnydale, Calif.) at an excitation wavelength of
365 nm and an emission wavelength of 460 nm. A standard curve using calf
thymus DNA was used to calibrate the fluorometer. NP-40 (Sigma, St. Louis,
Mo.) was added to the remaining brain homogenate to a final concentration of
1%, and the lysate was clarified by centrifugation at 16,000 	 g at 4°C. The
protein concentration of the supernatant was determined by a BCA protein
assay. Data are expressed as percentages of the mean wild-type value, presented
as means 
 standard deviations (SD) for one experiment with littermate con-
trols. Experiments were repeated at least three times.
Measurements of cardiomyocyte size. Hearts dissected from age- and sex-
matched mutant and wild-type animals were fixed overnight in 10% neutral
buffered formalin (NBF) (Sigma). After fixation, hearts were cut sagittally, em-
bedded in paraffin, and sectioned. Five-micrometer sections were deparaffinized,
stained with fluorescein isothiocyanate (FITC)-conjugated wheat germ aggluti-
nin (Vector Laboratories Inc., Burlingame, Calif.), counterstained with pro-
pidium iodide, and then analyzed by microscopy with a Nikon Eclipse TE300
microscope (34). Two to eight 20	 fields were analyzed per animal. The myocyte
cross-sectional area was quantified by using the FITC-demarcated outline of the
cell and Metamorph software (Universal Imaging Corporation, Downingtown,
Pa.).
Analysis of cell density. Animals were anesthetized with pentobarbital and
then perfused with phosphate-buffered saline containing 10 U of heparin/ml
followed by 10% NBF. Brains were dissected, fixed overnight in 10% NBF, and
transferred to 50 mM Tris–150 mM NaCl, pH 7.6, prior to being processed and
embedded in paraffin. Six-micrometer sections were cut by use of a rotary
microtome. Every other section was stained with cresyl violet. Sections were
matched by the use of anatomic landmarks and a mouse brain atlas. Sections
between 0.14 and 0.21 mm anterior to the bregma were deparaffinized and
stained with 10 g of Hoechst 33258/ml (Sigma). Quantification of the number
of nuclei per defined area of motor cortex was performed with the Metamorph
image analysis suite, and the mean cell area was expressed as the field area per
number of cells. Three areas per slide were evaluated. Four to seven slides were
evaluated per animal. Micrographs of motor cortexes were obtained with a
cooled charge-coupled device camera (Princeton Instruments).
Livers isolated from Akt1- and Akt3-null mice were fixed in 10% NBF over-
night, rinsed in phosphate-buffered saline, and then embedded in paraffin. Six-
micrometer sections were cut by use of a rotary microtome. Sections were
deparaffinized and stained with Hoechst 33258. The density was measured and
the mean cell area was calculated as described above.
Statistical analysis. For comparisons between mutant and wild-type groups,
Student’s two-tailed t test was utilized and significant P values are indicated. The
representative experiments shown were repeated at least three times.
RESULTS
Akt3 expression and generation of Akt3-deficient mice. Al-
though the phenotypes of mice deficient in Akt1 and Akt2 are
now well established, little is known about the role of Akt3 in
mammals. For this reason, we generated mice in which the
FIG. 2. Akt protein expression. (A) Tissues from three adult fe-
male wild-type mice were isolated for protein analysis. The amount of
Akt3 protein in each tissue relative to the amount in the wild-type
brain is depicted, and a representative Western blot is shown. Data for
brains isolated from adult Akt1 (1KO)-, Akt2 (2KO)-, and Akt3
(3KO)-deficient mice are shown for comparison. The graph represents
means 
 SD for three blots. (B) Brains were dissected from three
adult wild-type C57BL/6 mice, and the cortices, hippocampusi, and
cerebella were isolated and homogenized for Akt protein measure-
ments. Two dilutions (10 g [a] and 20 g [b]) from each sample were
subjected to Western blot analysis. A standard curve of the recombi-
nant protein for each isoform was used to quantify the amount of Akt
in the lysate (as detailed in Materials and Methods). The mean
amounts of protein in the two dilutions and the standard deviations are
depicted by the bar graph, and a representative Western blot is shown
below.
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expression of the Akt3 gene was eliminated by standard tar-
geting in embryonic stem cells (Fig. 1). As a consequence of
this mutation, the Akt3 protein was undetectable in brains of
knockout animals (Fig. 2A). Akt3 nullizygous animals were
born at a Mendelian frequency and did not exhibit any overt
abnormalities for at least 1 year.
To search for potential phenotypic consequences of the
Akt3 elimination that were not immediately obvious, we re-
evaluated the tissue distributions of Akt isoforms in the adult
mouse, keeping in mind that mRNA and protein levels are not
always in correlation, as, for example, in the case of Akt1 (76).
Of all the mouse tissues examined, Akt3 expression was high-
est in the brain, which was consistent with the mRNA expres-
sion pattern (Fig. 2A). However, when we compared relative
levels of mRNA and protein in different organs, protein ex-
pression, unlike mRNA expression, was observed in the heart,
ovaries, and spleen (76).
To evaluate the relative expression of each of the Akt pro-
teins in the brain, we developed an assay using isoform-specific
antibodies and recombinant protein standards to quantify the
absolute amounts of Akt1, -2, and -3. In adult brains, Akt3 was
the predominant isoform, representing about one-half of the
total Akt protein, whereas Akt1 accounted for approximately
30% of the total and Akt2 made up the rest (Fig. 2B). In
postnatal day 1 brains, Akt1 was more abundant, accounting
for 47% of the total Akt protein, whereas the relative levels of
Akt2 and Akt3 were 14 and 39%, respectively (data not
shown). Akt3 was present in all regions of the adult mouse
brain and was the predominant isoform in the cortex and
hippocampus. On the other hand, Akt2 was the most expressed
isoform in the cerebellum, whereas Akt1 was the major iso-
form in the spinal cord (Fig. 2B).
Regulation of brain size by Akt3. Considering that Akt is
required for the attainment of normal organ and organismal
size in D. melanogaster and mice (13, 17, 61, 71) and that Akt3
is highly expressed in the mouse brain, we measured the brain
weights of mutants lacking Akt3. Akt3-deficient mice demon-
strated a reduction in brain size, as brains from adult nullizy-
gotes were 25% smaller than those of their wild-type litter-
mates, expressed either in absolute terms (349 
 14.0 mg
versus 464 
 11.7 mg; N  6 or 7; P  0.001) (Fig. 3A and B)
or as a ratio to body weight (Table 1). However, mouse size
was unaffected by the Akt3 deficiency (Fig. 3C and D), and all
organs examined other than the brain were normally sized
(Table 2). Even the testes, which, like ovaries, had the second
highest level of Akt3 protein expression, were normal in size in
Akt3-deficient male mice (data not shown). Thus, the reduc-
tion in organ size in Akt3/ mice was specific to the brain and
was not proportional to body size (Table 2). This abnormality
was present at birth, with postnatal day 1 mice displaying a
15% reduction in brain size compared to wild-type mice (68 

7.7 mg versus 80 
 7.5 mg; N  13 to 24; P  0.00), despite
their normal body size (1.4 
 0.14 g for Akt3/ animals versus
1.4 
 0.17 g for Akt3/ animals; N  13 to 24) (Table 1). The
relative reduction in brain size compared to the wild type
continued to increase during the first 3 weeks of life, reaching
the same degree as that seen in adults by the end of the third
week (394 
 19.1 mg for Akt3/ animals versus 302 
 21.7 mg
for Akt3/ animals; N  4 or 5; P  0.01).
To obtain a more quantitative estimate of the relationship
between brain size and body weight, we performed an allomet-
ric analysis. Thus, we plotted the corresponding weight values
for wild-type and Akt3 knockout mice as a logarithmic trans-
formation of the scaling equation y  axb and performed a
linear regression analysis. This allowed us to determine the
slope of the regression line, or allometric exponent b, which
represents a formal quantitative measure of the relationship
between x and y, in this case body weight and brain weight (Fig.
4). For wild-type mice, b  0.75, which is in close approxima-
tion to that previously reported for mammals (47). In contrast,
the value of b (0.61) for Akt3-deficient mice indicated that the
brain size for a given body weight was significantly reduced.
Next, we considered possible effects of the Akt3 mutation on
myelination, which begins during the first week of postnatal
brain development and peaks within the third to fourth week
of life (33, 52). IGF1 has been implicated in the control of this
process, as its overexpression increases myelination (11).
Moreover, IGF1-deficient brains have decreased myelination,
FIG. 3. Selective reduction of brain size in Akt3-deficient mice.
(A) Brains were dissected from 30-week-old wild-type (WT) and Akt3-
deficient (3KO) mice. (B) Plot of adult brain weights from Akt3 knock-
out mice and littermate controls (N  6 or 7). The mean value is shown
by a horizontal red bar. The asterisk indicates that P  0.001 for
wild-type versus Akt3-deficient brains. Male (C) and female (D) mice
were weighed periodically during the first 8 weeks of life. Filled circles
represent wild-type mice; open circles depict Akt3-deficient mice. Val-
ues are means 
 standard errors of the means (SEM) (N  15 to 20).
TABLE 1. Ratios of brain weights to body weights in wild-type and
Akt3/ mice
Mouse
Weight ratioa (mg/g) (n)
P valueb
Wild type Akt3/
Postnatal day 1 55.9 
 5.66 (13) 50.0 
 6.37 (24) 0.01
Adult 14.3 
 1.41 (6) 11.6 
 1.93 (7) 0.05
a Data are means 
 SD.
b Comparing wild-type and Akt3/ mice.
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which is probably proportional to the reduction in cell number
(6, 14). The total myelin content was reduced by 20% in Akt3-
deficient brains (3.8 
 0.27 mg; N  7) compared to wild-type
brains (4.7 
 0.32 mg; P  0.005; N  4), which was commen-
surate with the decrease in brain size. Thus, when the myelin
content was corrected for the brain weight, there was no sig-
nificant difference between brains from Akt3-deficient (10.7 

0.73 g of myelin/mg of brain) and wild-type (9.8 
 0.78 g of
myelin/mg of brain) mice. We concluded, therefore, that a
reduction in myelin alone does not account for the decrease in
brain size in Akt3 knockout animals.
In Drosophila, the Akt homolog Dakt1 regulates organ size
primarily by the control of cell growth, although the cell num-
ber can also influence organ volume (29, 71). To clarify how
Akt3 controls mammalian brain size, we measured the DNA
and protein content in brains from Akt3-null mice. In the
absence of polyploidy, the total DNA content reflects the cell
number, whereas the protein-to-DNA ratio conveys informa-
tion about cell size. For example, if an organ were smaller
because the cell number was reduced, then the total DNA
content would be decreased but the protein-to-DNA ratio
would remain unchanged. If cell size alone were decreased,
then the protein content would be reduced but the total DNA
content would be unaffected, thereby producing a decrease in
the protein-to-DNA ratio.
In Akt3-deficient mice, the brain had a 13% decrease in total
DNA content and an 11% reduction in the protein-to-DNA
ratio (Table 3). This suggested that the 25% size reduction in
the Akt3-deficient brain was secondary to both a decrease in
cell number and a reduction in cell size. To obtain an inde-
pendent measure of cell size, we measured the cell density in
the adult cortex of Akt3-deficient brains and calculated the
mean cell area. Using Hoechst 33258, we labeled nuclei in
serial sections from matched regions of cerebral cortex and
counted the number of nuclei in a defined area in both wild-
type and knockout brains. In Akt3-deficient brains, the number
of nuclei in the defined area was increased, indicative of a
smaller mean cell area (Fig. 5). This reduction in cell size may
be secondary to a change in the cell body size or to decreases
in the number and size of dendrites. In neuronal cultures,
inhibitory Akt constructs result in both diminished axon elon-
gation and diminished soma size (46). In organs that were
unaffected by the Akt3 deficiency, such as the liver and the
heart (Table 2), which retained their normal sizes, no change
in cell size was observed (data not shown), while the total DNA
content and the protein-to-DNA ratio remained at wild-type
levels (Table 3). We noted that the density of hepatocytes and
the mean area of cardiomyocytes were normal in Akt3-defi-
cient mice.
Analysis of metabolism in Akt3-deficient mice. In addition
to regulating growth, the PI3K/Akt pathway is also required for
normal metabolism. For example, Akt2 regulates glucose ho-
meostasis, as mice deficient in this isoform are hyperinsuline-
mic and hyperglycemic (16, 29). Akt3 is expressed in cultured
adipocytes and its activity is increased by insulin, raising the
possibility that Akt3 is also important for the regulation of
glucose or fat metabolism (5). Nevertheless, serum insulin,
glucose, and free fatty acids were normal in Akt3-null mice
(Table 4). In addition, adult Akt3-deficient mice exhibited
glucose and insulin tolerance that was indistinguishable from
that of wild-type mice (Fig. 6). Thus, we were unable to detect
abnormalities in carbohydrate metabolism in Akt3/ mice.
Comparison of Akt3 mutants to Akt1- and Akt2-null mice.
Akt1-deficient mice exhibited a 14% reduction in brain size
compared to littermate controls (383 
 32.9 mg versus 446 

8.6 mg; N  5; P  0.01) that was proportional to the reduction
in body size. An analogous maintenance of normal organ size
FIG. 4. Allometric plot. A log-log plot with first-order regression of
the brain weights (BR) of wild-type and Akt3 knockout mice versus
their corresponding body weights (BW) determined at postnatal days
3, 7, 12, 16, 20, 21, and 23 is shown. The results of the corresponding
regression analyses were as follows: for wild-type mice, BR 
0.08BW0.75 (r  0.97); for Akt3 knockout mice, BR  0.09BW0.61 (r 
0.98).
TABLE 2. Comparison of organ-to-body-weight ratios for wild-type (Akt3/) and Akt3-deficient (Akt3/) miceb
Organ
Weight (mg) % Body weight (relative to control)
P valuea
Akt3/ (n  6) Akt3/ (n  5) Akt3/ (n  6) Akt3/ (n  5)
Kidney 248 
 17.7b 246 
 38.0 100 
 10.4 100 
 15.1 NS
Liver 1,761 
 56.4 1,550 
 169.2 100 
 7.1 93 
 11.9 NS
Spleen 122 
 29.1 141 
 65.4 100 
 24.4 100 
 47.8 NS
Heart 213 
 45.0 228 
 22.3 100 
 23.9 113 
 17.5 NS
Thymus 40 
 4.0 42 
 1.1 100 
 9.5 100 
 19.2 NS
Brain 432 
 23.0 338 
 20.3 100 
 9.1 82 
 6.2 0.01
Body 34 
 1.9c 32 
 3.0c
a Comparing wild-type and Akt3/ mice. NS, not significant (P  0.05).
b Data are means 
 SD.
c Body weights are given in grams.
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for body size was also observed for the livers and hearts of
Akt1 nullizygotes (data not shown). Akt2-null mice displayed
no change in brain size compared to control animals (431 

19.3 mg versus 439 
 20.6 mg; N  4).
Unlike Akt3, Akt1 was required for the size control of other
organs, such as the heart and liver, in addition to the brain. In
Akt1-deficient brains, the total DNA content was reduced by
21% and there was a trend towards an increased protein/DNA
ratio that did not achieve statistical significance (Table 3).
These data suggest that Akt1 is required mainly for the deter-
mination of the proper cell number. As performed with Akt3-
deficient brains, we labeled nuclei in serial sections from
matched regions of the cerebral cortex and counted the num-
ber of nuclei in a defined area in both wild-type and Akt1
knockout brains. We found no difference in the numbers of
nuclei per area in Akt1-deficient cortices compared to wild-
type controls (Fig. 7A to C). While Akt1 affected the cell
number in the brain, Akt1-deficient hearts had a normal cell
number, as indicated by an unchanged total DNA content
compared to wild-type hearts (Table 3). However, hearts from
Akt1/ mice displayed a 21% reduction in the protein-to-
DNA ratio, suggesting that the cells were smaller (Table 3).
This was confirmed by direct measurements of myocyte cross-
sectional areas by light microscopy (Fig. 7D to F). Akt1-defi-
cient cardiomyocytes were 19% smaller than wild-type heart
cells (202 
 12.7 m2 versus 249 
 13.6 m2; N  5; P  0.01)
(Fig. 7D to F). The same result was obtained when the number
of nuclei was counted in each field and when the mean cell size
was computed as performed for brains (data not shown).
Unlike the heart, the Akt1-deficient liver revealed a normal
protein-to-DNA ratio, suggesting an appropriate cell size, but
had a 25% reduction in the total DNA content, which was
representative of a decrease in cell number (Table 3). As
described above for the heart and brain, liver sections from
Akt1-deficient and Akt1 wild-type mice were stained with
Hoechst 33258, and the numbers of nuclei were determined for
defined fields. The cell density did not differ between Akt1
knockout and wild-type liver sections (1,745 
 44.6 cells/mm2
versus 1,755 
 41.5 cells/mm2; N  3), indicating that there
was no change in the mean cell area (473 
 35.5 m2 for
Akt1/ animals versus 536 
 43.5 m2 for Akt1/ animals).
Thus, livers from Akt1/ mice were smaller due to an overall
decrease in the number of cells.
Differential activation of downstream targets by Akt iso-
forms. One explanation for the distinct effects of Akt1 and
Akt3 in the brain may be that the different isoforms of Akt
regulate unique downstream targets. The mTOR-p70 S6 ki-
nase pathway, which is downstream of Akt, regulates cell size
(55) and is active during the period of brain growth throughout
FIG. 5. Cell size in the Akt3-deficient brain. (A and B) Sections of
cortex stained with Hoechst 33258. Bar  100 m. (C) Mean cell areas
based on nuclear densities. *, P  0.001 for Akt3 knockout (KO)
versus wild-type (WT) brains.
FIG. 6. Metabolism in Akt3-deficient mice. (A and B) Glucose
tolerance tests were performed with male (A) and female (B) mice as
described in Materials and Methods. Values represent means 
 SEM
(N  8 to 10). Filled squares represent wild-type mice; open squares
depict Akt3-deficient mice. (C and D) Insulin tolerance tests were
performed with male (C) and female (D) mice as described in Mate-
rials and Methods. Values represent means 
 SEM (N  8 to 10).
Filled squares represent wild-type mice; open squares depict Akt3-
deficient mice.
TABLE 3. DNA and protein levels in organs from Akt knockout micea
Organ
Total DNA (% of wild type) Protein/DNA ratio (% of wild type)
Akt1 Akt3 Akt1 Akt3
Wild-type Knockout Wild-type Knockout Wild-type Knockout Wild-type Knockout
Brain 100 
 7.9 79 
 4.8b 100 
 1.1 87 
 1.3c 100 
 8.3 123 
 9.4 100 
 2.6 89 
 4.0c
Heart 100 
 12.9 109 
 20.3 100 
 0.7 97 
 1.0 100 
 8.8 78 
 11.8c 100 
 4.2 106 
 3.2
Liver 100 
 1.5 75 
 1.3b 100 
 0.7 105 
 3.0 100 
 3.3 108 
 3.2 100 
 3.3 95 
 5.1
a N  3 to 5 for each group.
b P  0.05 for wild-type versus knockout animals.
c P  0.01 for wild-type versus knockout animals.
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the first two postnatal weeks (69). mTOR is also required for
the growth induced by PTEN activation (36). Therefore, we
evaluated the phosphorylation of ribosomal protein S6, a
downstream target of mTOR, in brains isolated from postnatal
day 1 mice, in which p70 S6 kinase demonstrates peak activity
(69). In Akt3 knockout brains, ribosomal protein S6 phosphor-
ylation was decreased almost 50%. However, no reduction was
observed in Akt1-null brains (Fig. 8). Similarly, the phosphor-
ylation of p70 S6 kinase at serine 389 was reduced by 30% in
Akt3-deficient brains, while no significant alteration was ob-
served in Akt1 mutant brains (data not shown). Thus, Akt3 is
required for the normal phosphorylation of p70 S6 kinase and
its target, ribosomal protein S6, during postnatal brain growth.
DISCUSSION
Our analysis of the Akt3 null phenotype has provided the
first evidence of a nonredundant function for this protein ki-
nase in mammals. Similar to the closely related isoform Akt1,
Akt3 does not appear to contribute significantly to the main-
tenance of normal metabolism but is critical for the attainment
of normal organ size. However, in marked contrast to Akt1,
Akt3 does not regulate organismal size but controls exclusively
the mass of the mouse brain by influencing both cell size and
number, most likely, at least in part, through the selective
activation of downstream effectors in the mTOR pathway.
Now that experiments with fruit flies and mice have convinc-
ingly demonstrated a role for the PI3K/Akt pathway in the
control of cell and compartment size, the question arises of
how specificity is achieved given the large number of regulatory
processes for which Akt appears to function as an essential
intermediary (62). Although some of the previous studies that
considered this issue relied on knockout strategies like ours,
most reports have been based on overexpression studies of
wild-type, constitutively active, or dominant-negative mutants
(20, 22, 46, 66). We have reported previously that at least some
of the specificity of Akt signaling, when growth versus metab-
olism is considered, is conferred by dissimilarities between
Akt1 and Akt2 and that differences intrinsic to the Akt pro-
teins contribute to selective signaling (3, 16, 17). The present
study extends those observations by providing the unexpected
FIG. 7. Cell size in Akt1-deficient brains and hearts. (A and B)
Sections of cortex stained with Hoechst 33258. Bar  50 m. (C) Mean
cell areas based on nuclear densities. (D and E) Micrographs of sec-
tions of hearts from Akt1 knockout mice (E) and littermate controls
(D) were stained with FITC-conjugated wheat germ agglutinin (green)
and propidium iodide (red). (F) The mean cell area of cardiomyocytes
is represented as a percentage of the mean wild-type control value.
Values are means 
 SD (N  3). *, P  0.01 for Akt1 knockout
myocyte size versus wild-type control size.
FIG. 8. Phosphorylation of ribosomal protein S6 in brains from
Akt-deficient mice. (A and C) Lysates (25 g) from postnatal day 1
brains were resolved by SDS-PAGE, transferred to a nitrocellulose
membrane, and probed for phosphorylated ribosomal protein S6 (P-
S6) or total S6 ribosomal protein as indicated. Each lane represents a
lysate from an individual animal. (B and D) The intensities of phos-
phorylated ribosomal protein S6 from several experiments were nor-
malized to that of the total S6 ribosomal protein and expressed as
percentages of the mean wild-type value. The data shown are means 

SD (N  3 to 6). *, P  0.01 for Akt3 knockout versus wild-type
littermates.
TABLE 4. Circulating metabolites in Akt3 knockout mice
Metabolic parametera
Value for males Value for females
Wild-type Knockout Wild-type Knockout
Fasting insulin (ng/ml) 0.363 
 0.0214 0.399 
 0.0601 0.365 
 0.0394 0.427 
 0.0539
Fasting glucose (mg/dl) 72 
 1.6 79 
 3.1 79 
 5.9 87 
 5.9
Fed glucose (mg/dl) 145 
 5.6 159 
 11.4 ND ND
Fed FFA (mEq/liter) 0.25 
 0.055 0.20 
 0.035 0.20 
 0.011 0.22 
 0.032
Fasting FFA (mEq/liter) 1.11 
 0.046 1.10 
 0.112 0.98 
 0.074 1.00 
 0.062
a Data are means 
 SD. N  7 for each group. FFA, free fatty acids; ND, not done.
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result that two Akt isoforms, Akt1 and Akt3, are both essential
for normal growth control but that each functions in a distinct
manner. Whereas Akt1 is important for global, organismal
growth, the requirement for Akt3 is remarkably organ specific.
It is likely that the mechanism is cell autonomous, because
fibroblasts immortalized from Akt1-null mice also demonstrate
a reduced size (4, 59; K. Roovers and M. J. Birnbaum, unpub-
lished observations). Thus, growth control may be exerted by
each Akt isoform operating as a signaling intermediate within
the target cell. However, evidence that Akt1 and Akt3 have
dissimilar signaling capabilities and do not simply function
interchangeably is provided by the observation that the loss of
each of the isoforms leads to a decreased brain size by distinct
mechanisms, i.e, a reduction in only the cell number for
Akt1/ mice and in both cell size and number in Akt3/
mutants. A probable explanation is that the activation of iso-
form-specific signaling pathways accounts for much of the dif-
ference, which is further modulated by external, developmen-
tally regulated processes. For example, Akt3, but not Akt1, is
required for appropriate ribosomal protein S6 phosphorylation
during the postnatal period of brain growth (Fig. 8). However,
these differences may be tissue specific, and Akt1 may be
important for ribosomal protein S6 phosphorylation in the
heart, where Akt1 controls cell size. In addition, selectivity in
the ability of proximal signaling pathways to regulate Akt iso-
forms probably contributes to specificity. The elimination of
the gene encoding IRS2, a scaffolding protein thought to lie
upstream of Akt in a linear signaling pathway, results in an
impairment of brain growth secondary to a decrease in neuro-
nal proliferation (63). Interestingly, no change in cell survival
or cell size was observed for IRS2-null brains, suggesting that
IRS2 might preferentially regulate Akt1 in the brain, which
would be surprising given the similarities between the roles of
IRS2 and Akt2 in the control of peripheral metabolism (16, 29,
74). In addition, other induced mutations leading to organis-
mal growth deficiencies, such as an IRS1 deficiency, cause a
decrease in brain size and more closely resemble the pheno-
type of Akt1-null mice (1, 13, 17, 35, 76). Interestingly, in
contrast to the case for Akt1/ mice, for models based on a
loss of IRS1, the diminution in brain size is not as severe as the
reduction in body size (6, 63). This may occur because the
IRS1-deficient animals are smaller than Akt1 knockout ani-
mals, and a commensurate reduction in brain size may not be
compatible with life.
Previous studies have demonstrated that the activation of
Akt by the deletion of PTEN affects brain size (30, 37). Since
a PTEN deficiency modulates other targets in addition to Akt,
it is important to demonstrate, as shown here, that this kinase
is indeed a critical member of the pathway regulating normal
brain growth. In mature neurons, the increase in brain size
secondary to a targeted deletion of PTEN is a consequence of
the increase in cell size and is dependent on the activation of
mTOR (36). The deletion of PTEN at an earlier stage of
neuronal development leads to both enlarged and more abun-
dant cells (30). This suggests that the different phenotypes
observed for Akt1/ and Akt3/ mice may be related to the
stage of neuronal development at which each isoform is active,
with Akt3 being more critical for the later periods of brain
growth (21). The increased expression of the Akt3 protein in
the adult brain is consistent with this hypothesis.
Several publications have reported experiments with brains
and isolated neurons that implicate Akt in neuronal functions
such as survival (20, 22, 32), process formation (54), cell growth
(46), and synaptic plasticity (72). Unfortunately, these studies
have relied on constitutively active or putative dominant-neg-
ative forms of Akt, which, in addition to their inherent prob-
lems of specificity, do not address Akt isoform selectivity. In
this study, we confirmed the role of Akt in cell growth by using
a loss-of-function strategy and further defined Akt1 and Akt3
as being the most important isoforms for this process in the
brain. These genetic studies do not resolve, however, whether
the reduction in cell number in the Akt3/ brain is due to a
defect in proliferation or survival. It has been argued that
much of the macrocephaly in the brain-specific PTEN knock-
out is due to an expansion of central nervous system stem cells
via increased proliferation (30). Akt has also been strongly
implicated as a major regulator of the progression through the
G1 and G2 phases of the cell cycle (41). Whether the lack of
Akt1 and/or Akt3 decreases the cell number by affecting the
proliferative capacity of stem cells will need to be evaluated in
future studies. Interestingly, the microcephaly and macroceph-
aly of humans that are observed in IGF1-deficient patients and
patients with the Lhermitte-Duclos PTEN deficiency syn-
drome, respectively, result in cognitive defects such as mental
retardation (40, 75). This suggests a link between Akt and
higher cerebral function that has not yet been studied in detail.
Recently, a decrease in the Akt1 protein in the brain has been
linked to schizophrenia (25). This is supported by the obser-
vation that a mutation in Akt1 leading to a decreased amount
of protein increased the risk of schizophrenia, while the anti-
psychotic drug haloperidol was shown to activate Akt signaling
(25). In rodents, the PI3K pathway has been implicated in
memory formation (42, 49), which is often impaired in schizo-
phrenic patients (26).
Finally, note that although the reduction in organ mass in
Akt1-deficient mice was proportional to body size, the mech-
anism of this decrease depended on the tissue. Some indication
that this is the case is provided by the observation that in
Akt1/ Akt2/ mice, skeletal muscle atrophy is due to de-
creased myocyte size, whereas there is a reduced number of
cells in the skin (58). These organ-specific differences in the
modes of mass reduction may reflect the growth potential of
particular organs. For example, the heart enlarges in the post-
natal period exclusively through increases in cell size, whereas
the liver maintains a proliferative capacity (60). It is perhaps
for this reason that Akt1-deficient livers have decreased cell
numbers, whereas Akt1-deficient hearts have smaller cells.
Previous studies in which Akt activity was reduced in the heart
have yielded contradictory results. The expression of a kinase-
deficient Akt1 did not affect cardiac size, whereas a dominant-
negative PI3K reduced the heart mass significantly (65, 66).
This difference might be attributable to more attenuation in
the total Akt activity produced by the mutant PI3K or to
nonspecific actions of the dominant inhibitory form (19, 65). In
this study, we have shown that Akt1 activity is required for the
attainment of normal cardiomyocyte and heart size. This find-
ing further serves to emphasize the remarkable capacity of the
metazoan organism to coordinate the growth of individual
organs and the critical role of Akt in this process.
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